ArticleJHLT open2024
Direct oral anticoagulants versus warfarin in adult heart transplant recipients.
Article in JHLT open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Direct oral anticoagulants (DOACs) have transformed the field of anticoagulation, offering more predictable pharmacokinetic and pharmacodynamic characteristics when compared to traditional warfarin therapy. DOAC use in the heart transplant population is particularly important to further study due to the high risk of venothromboembolism and the potential for significant drug interactions and altered pharmacokinetics post-transplantation. Methods: A single center, retrospective cohort study was performed in adult heart transplant recipients requiring anticoagulation following transplantation between January 2010 and July 2021. Primary outcomes included incidence of bleeding and breakthrough thromboembolic events. Results: Ninety-five patients met inclusion criteria and out of these patients, 30 (32%) were prescribed warfarin and 65 (68%) were prescribed a DOAC. Seventeen total bleeding events occurred. Bleeding events were significantly more common in the warfarin group compared to the DOAC group (58% vs 41%, Conclusion: DOAC therapy in heart transplant recipients may be safer from a bleeding perspective when compared to warfarin. Additional data to further evaluate the appropriateness for dose modifications for patients with potential drug-drug interactions, higher bleed risk, and unstable renal function are needed to guide optimal practice and dosing strategies in heart transplant recipients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.